MedTrace Logo

Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside

NCT01914081 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-11-14

No results posted yet for this study

Summary

The purpose of this study is to determine if resveratrol can improve heart function and quality of life. Although, population studies have revealed that a mild to moderate intake of red wine reduces cardiovascular disease risk in humans, clinical studies that evaluate the potential heart benefits of resveratrol in patients with non-ischemic cardiomyopathy have not been previously reported. Accordingly, this research is being done because it will fill this deficiency in the information available in the literature and establish the clinical benefits of resveratrol in patients with this type of heart disease.

Conditions

  • Dilated Cardiomyopathy

Interventions

OTHER

Resveratrol

Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period

OTHER

Placebo

Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period

Sponsors & Collaborators

  • Canadian Centre for Agri-Food Research in Health and Medicine

    collaborator OTHER

  • Agriculture and Agri-Food Canada

    collaborator OTHER_GOV

  • Manitoba Medical Service Foundation

    collaborator OTHER

  • St. Boniface Hospital

    lead OTHER

Principal Investigators

  • Shelley Zieroth, MD · St. Boniface Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-09
Primary Completion
2019-11-30
Completion
2020-11-30
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01914081 on ClinicalTrials.gov